RU2021110230A - Комбинированные способы терапии для лечения злокачественной опухоли - Google Patents
Комбинированные способы терапии для лечения злокачественной опухоли Download PDFInfo
- Publication number
- RU2021110230A RU2021110230A RU2021110230A RU2021110230A RU2021110230A RU 2021110230 A RU2021110230 A RU 2021110230A RU 2021110230 A RU2021110230 A RU 2021110230A RU 2021110230 A RU2021110230 A RU 2021110230A RU 2021110230 A RU2021110230 A RU 2021110230A
- Authority
- RU
- Russia
- Prior art keywords
- bchl
- rgd
- agent
- pdt
- stl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 16
- 201000011510 cancer Diseases 0.000 title claims 5
- 238000002648 combination therapy Methods 0.000 title claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 13
- 238000002428 photodynamic therapy Methods 0.000 claims 13
- 125000000129 anionic group Chemical group 0.000 claims 10
- 239000000816 peptidomimetic Substances 0.000 claims 10
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 150000001768 cations Chemical class 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 108010049593 padeliporfin Proteins 0.000 claims 4
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- -1 anionic bacteriochlorophyll derivative Chemical class 0.000 claims 2
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662320549P | 2016-04-10 | 2016-04-10 | |
| US62/320,549 | 2016-04-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018139523A Division RU2747258C2 (ru) | 2016-04-10 | 2017-04-10 | Комбинированные способы терапии для лечения злокачественной опухоли |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021110230A true RU2021110230A (ru) | 2021-05-26 |
Family
ID=58794130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021110230A RU2021110230A (ru) | 2016-04-10 | 2017-04-10 | Комбинированные способы терапии для лечения злокачественной опухоли |
| RU2018139523A RU2747258C2 (ru) | 2016-04-10 | 2017-04-10 | Комбинированные способы терапии для лечения злокачественной опухоли |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018139523A RU2747258C2 (ru) | 2016-04-10 | 2017-04-10 | Комбинированные способы терапии для лечения злокачественной опухоли |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11278555B2 (https=) |
| EP (1) | EP3442582A1 (https=) |
| JP (2) | JP2019510807A (https=) |
| KR (2) | KR20190008206A (https=) |
| CN (2) | CN118304400A (https=) |
| AU (2) | AU2017250732B2 (https=) |
| BR (1) | BR112018070847A2 (https=) |
| CA (1) | CA3020067A1 (https=) |
| IL (1) | IL262191B2 (https=) |
| MX (2) | MX390751B (https=) |
| RU (2) | RU2021110230A (https=) |
| SG (1) | SG11201808849TA (https=) |
| WO (1) | WO2017179053A1 (https=) |
| ZA (1) | ZA201807187B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10107240B2 (en) | 2014-04-04 | 2018-10-23 | Dayco Ip Holdings, Llc | Check valves and Venturi devices having the same |
| CN106458190B (zh) | 2014-05-30 | 2019-12-06 | 戴科知识产权控股有限责任公司 | 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统 |
| EP3723785A1 (en) * | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Cop9 signalosome (csn) complex modulators and uses thereof |
| WO2022149934A1 (ko) * | 2021-01-08 | 2022-07-14 | 가톨릭대학교 산학협력단 | 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE347554T1 (de) | 1998-12-09 | 2006-12-15 | Yeda Res & Dev | Palladiumsubstituierte bakteriochlorophyllderivate und deren verwendung |
| IL133253A0 (en) * | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
| IL152900A0 (en) * | 2002-11-17 | 2003-06-24 | Yeda Res & Dev | Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses |
| PT2061512T (pt) | 2006-08-23 | 2020-01-14 | Yeda Res & Dev | Conjugados de péptidos com rgd e fotossensibilizantes de (bacterio)clorofila e as suas utilizações |
| US8673270B2 (en) | 2008-10-23 | 2014-03-18 | Steba Biotech S.A. | RGD-containing peptidomimetics and uses thereof |
| WO2012106343A2 (en) * | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| TWI442945B (zh) * | 2011-05-18 | 2014-07-01 | Univ Nat Taiwan | 雙效微脂體用於治療的方法 |
| WO2014141289A1 (en) * | 2013-03-12 | 2014-09-18 | Amrita Vishwa Vidyapeetham University | Photo - chemo composition on the basis of microcapsules with a core -shell structure |
-
2017
- 2017-04-10 KR KR1020187032029A patent/KR20190008206A/ko not_active Abandoned
- 2017-04-10 BR BR112018070847A patent/BR112018070847A2/pt not_active Application Discontinuation
- 2017-04-10 CN CN202410235521.9A patent/CN118304400A/zh active Pending
- 2017-04-10 MX MX2018012392A patent/MX390751B/es unknown
- 2017-04-10 US US16/092,742 patent/US11278555B2/en active Active
- 2017-04-10 WO PCT/IL2017/050440 patent/WO2017179053A1/en not_active Ceased
- 2017-04-10 JP JP2018553149A patent/JP2019510807A/ja active Pending
- 2017-04-10 SG SG11201808849TA patent/SG11201808849TA/en unknown
- 2017-04-10 CN CN201780035366.4A patent/CN109862918A/zh active Pending
- 2017-04-10 KR KR1020227034306A patent/KR20220139445A/ko not_active Abandoned
- 2017-04-10 RU RU2021110230A patent/RU2021110230A/ru unknown
- 2017-04-10 RU RU2018139523A patent/RU2747258C2/ru active
- 2017-04-10 CA CA3020067A patent/CA3020067A1/en active Pending
- 2017-04-10 IL IL262191A patent/IL262191B2/en unknown
- 2017-04-10 AU AU2017250732A patent/AU2017250732B2/en active Active
- 2017-04-10 EP EP17726380.3A patent/EP3442582A1/en not_active Withdrawn
-
2018
- 2018-10-10 MX MX2022003190A patent/MX2022003190A/es unknown
- 2018-10-26 ZA ZA2018/07187A patent/ZA201807187B/en unknown
-
2021
- 2021-11-29 JP JP2021193514A patent/JP2022031823A/ja active Pending
-
2022
- 2022-03-21 US US17/700,063 patent/US20220202838A1/en not_active Abandoned
-
2023
- 2023-02-06 AU AU2023200591A patent/AU2023200591A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3020067A1 (en) | 2017-10-19 |
| US20220202838A1 (en) | 2022-06-30 |
| AU2017250732B2 (en) | 2022-11-10 |
| WO2017179053A1 (en) | 2017-10-19 |
| MX2018012392A (es) | 2019-08-21 |
| IL262191B2 (en) | 2025-01-01 |
| RU2747258C2 (ru) | 2021-04-29 |
| IL262191B1 (en) | 2024-09-01 |
| ZA201807187B (en) | 2020-01-29 |
| RU2018139523A (ru) | 2020-05-15 |
| US11278555B2 (en) | 2022-03-22 |
| US20190125769A1 (en) | 2019-05-02 |
| EP3442582A1 (en) | 2019-02-20 |
| SG11201808849TA (en) | 2018-11-29 |
| MX2022003190A (es) | 2022-04-11 |
| CN109862918A (zh) | 2019-06-07 |
| KR20190008206A (ko) | 2019-01-23 |
| BR112018070847A2 (pt) | 2019-02-05 |
| MX390751B (es) | 2025-03-21 |
| JP2022031823A (ja) | 2022-02-22 |
| AU2017250732A1 (en) | 2018-11-15 |
| IL262191A (en) | 2018-11-29 |
| CN118304400A (zh) | 2024-07-09 |
| JP2019510807A (ja) | 2019-04-18 |
| KR20220139445A (ko) | 2022-10-14 |
| AU2023200591A1 (en) | 2023-03-09 |
| RU2018139523A3 (https=) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Muragaki et al. | Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors | |
| RU2021110230A (ru) | Комбинированные способы терапии для лечения злокачественной опухоли | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| RU2014150569A (ru) | Конъюгат фотосенсибилизатора и хитозана и его применение | |
| MX2020010676A (es) | Derivados de pladeniolida como agentes dirigidos al espliceosoma para tratar el cancer. | |
| EA202190403A1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство | |
| MX2022016554A (es) | Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida. | |
| AR123049A1 (es) | Compuestos terapéuticos y modos de uso | |
| JP2019510807A5 (https=) | ||
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| AR045811A1 (es) | 5- arilpirimidinas como agentes ainticancerigenos | |
| US10335608B2 (en) | Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics | |
| CO2025018532A2 (es) | Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2 | |
| WO2016102735A1 (es) | Células madre irradiadas para el tratamiento del cáncer | |
| Bistolfi | Localized amyloidosis and Alzheimer's disease: the rationale for weekly long-term low dose amyloid-based fractionated radiotherapy | |
| NZ760040A (en) | Methods of treating brain tumors using combination therapy | |
| RU2617090C1 (ru) | Способ фотодинамической терапии злокачественных опухолей | |
| CN102499924B (zh) | 二乙撑三胺五乙酸或乙二胺四乙酸或胺三乙酸修饰卟啉的用途 | |
| RU2682293C2 (ru) | Способ лечения рака легкого | |
| RU2514638C1 (ru) | Способ лечения лимфом органа зрения | |
| ES2607613T3 (es) | Métodos de planificación de terapia fotodinámica focal | |
| JP2016138151A (ja) | 腎細胞癌の改良された治療 | |
| RU2486933C1 (ru) | Способ профилактики рецидивов при хирургическом лечении злокачественных опухолей органов малого таза или неорганных опухолей забрюшинного пространства | |
| Golusiński et al. | Photodynamic therapy in palliative treatment of head and neck cancer | |
| Stranadko et al. | 24 PHOTODYNAMIC THERAPY FOR SKIN CANCER WITH CHLORIN DERIVATIVES UNDER THE OUTPATIENT CONDITIONS |